A structural map of KRAS(G12C), showing the AMG 510 molecule in the binding pocket. Amgen is a Participating Research Team member of the Berkeley Center for Structural Biology (BCSB), which maintains and operates five of the ALS beamlines. (Credit: Amgen)
An investigational cancer drug that targets tumors caused by mutations in the KRAS gene will be evaluated in phase 2 clinical trials, following promising safety and efficacy results in preliminary human studies and excellent results in animal studies.
The drug, developed by Amgen and currently referred to as AMG 510, is the first therapy to reach clinical trials that inhibits a mutant KRAS protein. Errors in the KRAS gene, which encodes a crucial cell signaling protein, are one of the most common causes of cancer.
The particular mutant inhibited by AMG 510 – called KRAS(G12C) – is present in approximately 13% of lung adenocarcinomas, 3% of colorectal cancers, and 2% of other solid tumors.
Despite its significant role in the pathogenesis of cancer, scientists have been unable to design KRAS-specific therapeutics due to the shape of the protein – it has an exceptionally smooth surface with no obvious regions for a drug molecule to bind. Seeking to develop a long-sought direct inhibitor, researchers at Amgen conducted X-ray crystallography of KRAS(G12C) proteins at Berkeley Lab’s Advanced Light Source (ALS). The high-resolution structural maps generated using the data acquired at the beamlines helped Amgen make the breakthrough discovery of a small pocket on the molecule. In subsequent studies, the beamline data allowed scientists to investigate atomic-level molecular interactions between KRAS(G12C) and potential inhibiting compounds that bind in this pocket. AMG 510 emerged as a very promising candidate after a multiyear drug agent optimization program.
“It’s rare that a compound gets all the way through the development process and becomes a drug. So, for the BCSB team, it feels great to see our (small) contribution finding its way to fight diseases,” said Marc Allaire, one of the Berkeley Lab biophysicists who operate the BCSB beamlines.
Learn more: Unique Cancer Drug Discovered With Help From Advanced Light Source Begins Historical Clinical Trial
Go deeper with Bing News on:
Investigational cancer drug
- Turning pain into purpose: Al Roker shares prostate cancer story, urges Black men to get testedon February 23, 2021 at 12:48 pm
By Black Health Matters Al Roker, America’s longtime beloved weatherman, journalist and television personality publicly revealed his prostate cancer diagnosis alongside his TODAY show co-hosts on Nov.
- U.K. and Canada Apply the Brakes to FDA Fast-Tracked Cancer Drugson February 23, 2021 at 1:32 am
For example, the United States often approves cancer therapies using a fast-track process, while that accelerated approach is seldom used in England or Canada, according to two studies published in ...
- Oncotarget: MEK is a promising target in the basal subtype of bladder canceron February 22, 2021 at 1:13 pm
Oncotarget recently published in "MEK is a promising target in the basal subtype of bladder cancer" by Merrill, et al. which reported that while many resources exist for the drug screening of bladder ...
- Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Canceron February 18, 2021 at 11:26 am
Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell ...
- Nektar Collaborates With SFJ Pharma For Bempegaldesleukin In Head And Neck Canceron February 17, 2021 at 5:32 am
SFJ Pharmaceuticals is a drug development company backed by Abingworth and Blackstone Life Sciences. The collaboration between SFJ and Nektar will support a new Phase 2/3 registrational clinical study ...
Go deeper with Google Headlines on:
Investigational cancer drug
Go deeper with Bing News on:
Cancer drug
- Cancer patients often can’t get full care with covid-19 bogging down medical facilitieson February 28, 2021 at 10:00 am
New vaccines promise relief. But any further surges in America’s hospitals and clinics will hamstring their ability to care for the sickest in oncology departments.
- Metro Vancouver mom turns to GoFundMe after pricey U.S. cancer drug hailed as 'her last hope'on February 28, 2021 at 6:25 am
There is nothing more important in the world to me, than being here to raise my baby." That's the message from Metro Vancouver mom Bree Jordan, who recently learned she has exhausted all possible ...
- Thousands of women with incurable breast cancer will benefit from new drug which can extend life by eight months after it receives NHS approvalon February 26, 2021 at 5:23 pm
Thousands of women with incurable breast cancer will benefit from a new life-extending drug on the health service.
- 5 Recent Cancer Drug Approvals Patients May Have Missedon February 26, 2021 at 11:02 am
Throughout the winter, the FDA has continued to approve several new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.
- Life-extending drug for incurable breast cancer approved for NHS useon February 26, 2021 at 8:28 am
About 3,300 women a year may benefit from decision to approve ribociclib ...
